News Flash >

Women's Health

 

Abnormal Methylation of Tumor Suppressor Ggenes Occurs in Sporadic Breast Cancer  (Russian Academy of Medical Science-November 5, 2003)


"Multiplex methylation-sensitive PCR was employed in studying the methylation of CpG islands in the RB1, p16/CDKN2A, p15/CDKN2B, p14/ARF, CDH1, MGMT, HIC1, and N33 promoter regions in breast cancer (105 tumors)," researchers in Russia report.

"Methylation was often observed for the two major suppressor genes involved in controlling the cell cycle through the Cdk-Rb-E2F signaling pathway, RB1 (18/105, 17%) and p16 (59/105, 56%); both genes were methylated in 13 tumors," wrote V.V. Zemlyakova and colleagues, Russian Academy of Medical Science, Medical Genetics Research Center.

The researchers concluded: "Methylation involved p15 in two (2%) tumors; CDH1, in 83 (79%) tumors; MGMT, in eight (8%) tumors, and N33, in nine (9%) tumors. The p14 promoter was not methylated in the tumors examined."

Zemlyakova and colleagues published their study in Molecular Biology (Abnormal methylation of several tumor suppressor genes in sporadic breast cancer. Mol Biol-engl Tr, 2003;37(4):591-597).

For additional information, contact V.V. Zemlyakova, Russian Academy of Medical Science, Medical Genetics Research Center, Moscow 115478, Russia.

The information in this article comes under the major subject area of Oncology. This article was prepared by Biotech Week editors from staff and other reports.

©Copyright 2003, Biotech Week via NewsRx.com & NewsRx.net

This story has been adapted from a news release issued by NewsRx.com & NewsRx.net